{"url_path":"/sec/tovx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-093782-index.html","accession_number":"0001104659-26-093782","cik":"0000894158","ticker":"TOVX","issuer_name":"Theriva Biologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-093782-index.html","primary_entity_key":"0000894158","primary_entity_name":"Theriva Biologics, Inc."},"word_count":184,"has_tables":true,"body_markdown":"**Item 2.02. Results of Operations and Financial\nCondition.**\n\n \n\nOn August 11, 2026, Theriva Biologics, Inc.,\na Nevada corporation (the “Company”), issued a press release that included financial information for its quarter ended June 30,\n2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein\nby reference.\n\n \n\nThe information in this Item 2.02 and in the press\nrelease attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections\n11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached\nas Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities\nand Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language\nin such filing."}